About ChomiX
Nanjing Kolosi Biotechnology Co., LTD., founded in March 2021, has completed two rounds of financing. In June 2022, the R&D base of 1700 square meters in Jiangbei New District of Nanjing was launched. It is one of the first domestic biotechnology enterprises based on the cross-field of chemical biology.
Colos Biotechnology focuses on small molecule innovative drug research and development, with chemical proteomics technology as the core, engaged in drug target discovery and lead compound screening of targeted drugs.
The company's main business segments are divided into two parts: innovative drug target discovery and innovative drug lead compound discovery. It strives to build a one-stop technology platform for target discovery and lead compound screening, providing comprehensive drug-related information from drug target analysis, drug structure optimization, drug safety evaluation and so on, to meet the market demand for new drug targets and drug structure.
Colossal Biosciences will always guide the development of the company with a pragmatic, rigorous, and pursuit of excellence scientific research spirit, adhere to "talent first, technology first, customer first", and use advanced technology to solve problems for customers and create value. Only by being down-to-earth can we look up at the stars. Colosse Bio will continue to research and develop its own core technology, and strive to always remain the number one on the track and lead the development of the industry.
